from the newsdesk, page-63

Would be handy to sign anyone with an approved drug, J&J included.

But I think its a long shot for Ustekinumab. Makes no sense for pharma to submit a drug in a prefill with needle guard and then upon months of receiving approval starting the expensive regulatory approval process again for a different syringe.

Stuff in clinical trials or long established drugs make more sense than recently approved.

Think about the cost of the drug used in the validation lots of filling and stability tests. A lot of labour, facility, QC lab, QA resources and drug that cant be sold all mean it would be wise to do this once in the primary container-syringe that you intend moving forward. Not to mention any supply agreement with existing syringe and needle guard suppliers and all the secondary packaging and labelling etc. Quite a lot of things to do.